Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

S. Szántó, G. Poór, D. Opris, O. Iaremenko, L. Procházková, R. Kuuse, O. Nagy, V. Chernyshov, P. Géher,

. 2016 ; 5 (5) : 475-85. [pub] 20160715

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011117

AIM: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. METHODS: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (≥50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or ≥1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. RESULTS: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. CONCLUSION: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011117
003      
CZ-PrNML
005      
20180426105310.0
007      
ta
008      
180404s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/cer-2016-0020 $2 doi
035    __
$a (PubMed)27417564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Szántó, Sándor $u Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
245    10
$a Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe / $c S. Szántó, G. Poór, D. Opris, O. Iaremenko, L. Procházková, R. Kuuse, O. Nagy, V. Chernyshov, P. Géher,
520    9_
$a AIM: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. METHODS: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (≥50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or ≥1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. RESULTS: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. CONCLUSION: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.
650    _2
$a adalimumab $x terapeutické užití $7 D000068879
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a psoriatická artritida $x farmakoterapie $7 D015535
650    _2
$a Evropa $7 D005060
650    _2
$a východní Evropa $7 D005061
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a ankylózující spondylitida $x farmakoterapie $7 D013167
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Poór, Gyula $u National Institute of Rheumatology & Physiotherapy, Budapest, Hungary.
700    1_
$a Opris, Daniela $u "Sf. Maria" Clinical Hospital, Bucharest, Romania.
700    1_
$a Iaremenko, Oleg $u National Medical University, Kyiv, Ukraine.
700    1_
$a Procházková, Leona $u Rheumatology Division, 2nd Department of Internal Medicine, St Anne's University Hospital Brno, Brno, Czech Republic.
700    1_
$a Kuuse, Reet $u Tartu University Hospital, Tartu, Estonia.
700    1_
$a Nagy, Orsolya $u AbbVie Ltd, Budapest, Hungary.
700    1_
$a Chernyshov, Valentyn $u AbbVie Biopharmaceuticals GmbH, Minsk, Belarus.
700    1_
$a Géher, Pál $u Hospitaller Brothers of St John of God Hospital, Budapest, Hungary.
773    0_
$w MED00195023 $t Journal of comparative effectiveness research $x 2042-6313 $g Roč. 5, č. 5 (2016), s. 475-85
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27417564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180426105421 $b ABA008
999    __
$a ok $b bmc $g 1288602 $s 1007929
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 5 $c 5 $d 475-85 $e 20160715 $i 2042-6313 $m Journal of comparative effectiveness research $n J Comp Eff Res $x MED00195023
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace